HSK-39297

iStockphoto/ Peshkova China’s Haisco Pharmaceutical continues to wield deals, this time out-licensing rights to two late-stage programs to New Jersey biotech Nuvectis. U.S. biotech Nuvectis is picking up the rights to two late-stage assets from China’s Haisco Pharmaceutical in a deal that could exceed $1.4 billion. For $40 million in upfront and near-term payments, Nuvectis has in-licensed exclusive worldwide rights—excluding China—for an oral complement Factor B inhibitor dubbed NXP100 and a paradox-breaker BRAF inhibitor called NXP200. Haisco has also held on to rights for NXP100 in India and specific Southeast Asia areas, according to a Monday release. NXP100 (formerly known as HSK39297) is a once-daily candidate currently under two regulatory reviews for China approval in a rare genetic blood disorder called paroxysmal nocturnal hemoglobinuria (PNH). The asset is also being evaluated in an ongoing Phase 3 trial for immunoglobulin A nephropathy and was assessed in a mid-stage study for lupus nephritis. “NXP100 is a late-stage Factor B inhibitor with the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for these diseases requiring life-long treatment,” Nuvectis CEO Ron Bentsur said in the release. The PNH market size is projected to surpass $5 billion in 2026, with AstraZeneca’s Alexion injectable C5 inhibitor drugs Soliris and Ultomiris expected to make up the bulk sum of that total, according to the release. Then there’s Novartis’ Fabhalta, which launched in 2024 as the only FDA-approved complement Factor B inhibitor. Nuvectis believes its newly acquired candidate could have a convenience edge over Fabhalta, which is administered orally twice a day. In late-stage PNH trials, treatment with either NXP100 or Fabhalta proved superior to treatment with C5 inhibitors, with a comparable effect for NXP100 and Fabhalta, according to Nuvectis. China Lilly bets $3B+ to add China’s Haisco to growing list of partners in five-program pact Eli Lilly and the Haisco Pharmaceutical Group have yet to disclose what specific indications they plan to prioritize. June 2, 2026 · 1 min read · Tristan Manalac Read more Meanwhile, NXP200 (coded by Haisco as HSK42360) is an oral paradox-breaker BRAF inhibitor—a next-gen version of BRAF inhibitors designed to be more selective and avoid activating some of the cell pathways that older versions trigger. The program is being studied in a Phase 1b study in China for BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, which include colorectal cancer, melanoma and non-small-cell lung cancer, among others. Under the terms of the deal, Haisco could collect up to $1.42 billion in biobucks, plus tiered royalties. In order for the pact to close, Nuvectis must meet several financing conditions to prove it has enough money to advance the licensed products. The deal propels public biotech Nuvectis into late-stage development. Previously, Nuvectis’ most advanced asset was NXP900, an oral small molecule inhibitor being studied in an ongoing Phase 1b study for advanced cancers. For Haisco, it marks another partnership in a long line of dealmaking, most notably with Big Pharmas Eli Lilly and AbbVie . Both licensing deals were inked in the second quarter of this year, with Lilly working on a clutch of early-stage programs with the China company and AbbVie entering into the pain medicine space via the deal. Pain AbbVie enters world of pain in up to $715M deal with China’s Haisco The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx. April 13, 2026 · 1 min read · Annalee Armstrong Read more

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies. NXP100 (HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated diseases. Current development status in China includes: Two Marketing Authorization Applications (MAAs) are under review for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH); The applications seek approvals for NXP100 for the treatment of PNH in treatment-naive patients and in patients who failed treatment with a Complement protein 5 (C5) inhibitor. Successful completion of a Phase 2 and ongoing Phase 3 trial in Immunoglobulin A Nephropathy (IgAN). Ongoing Phase 2 trial in Lupus Nephritis (LN). NXP200 (HSK42360): An oral, brain penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated malignancies. NXP200 has generated single agent durable responses in several tumor types including CNS, colorectal, melanoma, non-small-cell lung cancer, papillary thyroid and others. Paradox breaking represents a next generation approach to targeting BRAF. A Phase 1b study in China is ongoing. Strong intellectual property protection for both compounds. Nuvectis will hold a conference call today at 8:30 AM ET to introduce its newly in-licensed products. Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced a strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco Pharmaceutical Group (“Haisco”) to two potentially best in-class clinical-stage compounds. Nuvectis will hold a conference call today at 8:30 AM ET to introduce its newly in-licensed products. Haisco (SHE ticker code: 002653) is a leading fully-integrated pharmaceutical company with approximately 50 marketed products and 70 research programs, most recently recognized for successfully executing licensing deals with Eli Lilly and AbbVie (both in 2Q2026), and the phase 3 success of envudeucitinib in plaque psoriasis (1Q2026), a compound which Haisco discovered and advanced through development until it was licensed to Alumis, Inc. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “The in-licensing of the two clinical stage drug candidates with best-in-class potential represents an expansion of Nuvectis’ pipeline and strategy.” Mr. Bentsur continued, “NXP100 is a late-stage Factor B inhibitor with the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for these diseases requiring life-long treatment. With regards to NXP200, the paradox-breaker BRAF inhibitor, the ability to overcome the limitations of older generation BRAF inhibitors, a validated pharmaceutical class, is an area of great interest and we are very pleased to add NXP200 to our oncology pipeline, in which NXP900, our incumbent drug candidate, is progressing toward important clinical inflection points from the ongoing Phase 1b starting in this summer.” Mr. Bentsur concluded, “With tremendous in-house drug development capabilities and two recently completed licensing deals with Eli Lilly and AbbVie, Haisco is recognized as a premier drug development company with global reach. We are thankful for this opportunity and are privileged to partner with Haisco as we look forward to our collaboration and advancing these development programs.” Dr. Pangke Yan, Chief Executive Officer of Haisco, commented, “This licensing deal, in addition to our recently completed deals, further strengthens Haisco’s global research and development presence and we are excited to collaborate with Nuvectis on these two projects. We believe that Nuvectis has the relevant experience and capabilities required to advance these projects and that together we can accelerate and offer high-quality treatment options to patients worldwide.” Clinical / Regulatory Status in China and Key Data Summaries for NXP100 and NXP200 NXP100 (HSK39297) Paroxysmal Nocturnal Hemoglobinuria (PNH) Two MAAs for NXP100 have been submitted to the Chinese National Medical Products Administration (NMPA) and are currently under review: The first MAA is based on positive data from a completed randomized, open-label, active comparator-controlled, Phase 3 study (clinicaltrials.gov NCT06799546). In this study, 73 adult Chinese treatment naïve PNH patients were randomized 1:1 to receive either NXP100 or Soliris® (eculizumab), a Complement C5 inhibitor, for a 24-week treatment period. The primary efficacy endpoint was to evaluate the proportion of patients achieving hemoglobin (Hgb) levels ≥ 12 g/dL on at least three out of four measurements between Week 18 and Week 24 in the absence of red blood cell (RBC) transfusions. Treatment with NXP100 was superior to treatment with eculizumab in the primary and all key secondary endpoints (overall increase in Hgb levels, reducing the requirement for RBC transfusions, and avoiding extravascular hemolysis). Parameter NXP100 (n=37) Eculizumab (N=36) Primary Endpoint Proportion of participants achieving Hgb levels ≥12 g/dL without RBC transfusion % (95% CI) 59.5 (43.2, 75.7) 8.3 (2.8, 19.4) p-Value $5.0BN in 2026 with the injectable C5 inhibitor drugs Soliris® and Ultomiris®, marketed by Alexion/AstraZeneca Rare Disease, projected to be approximately $4.5BN of the total market. The PNH market is expected to more than double to >$10BN within 8 years. Soliris and Ultomiris were the centerpiece of Astra Zeneca’s acquisition of Alexion in 2021 for $39BN. Fabhalta (iptacopan, launched in 2024), marketed by Novartis, is the only FDA approved Complement Factor B inhibitor with approvals in PNH, IgAN and C3G. Fabhalta®is administered orally, twice per day, vs NXP100 which is administered once a day. Fabhalta® is currently also being investigated in several clinical trials, including LN, Myasthenia Gravis (MG) and dry Age-related Macular Degeneration (dAMD). Fabhalta® peak annual revenue in the currently approved indications is projected by analysts to reach $5B to $10B. The PNH and IgAN markets are estimated to reach >$20BN combined within the next 10 years. In randomized Phase 3 clinical trials in patients with PNH, treatment with either NXP100 or Fabhalta® was superior to treatment with C5 inhibitors, with comparable treatment effect for NXP100 and Fabhalta across studies, positioning CFBis to potentially dominate the PNH market over time. In IgAN, the Phase 2 data suggests that NXP100 has the potential to be comparable to the best injectable APRIL/BAFF inhibitors on the key renal function endpoints, including 24-hour UPCR and eGFR control. In cross study comparisons, the observed safety pro NXP100 appears to be similar to that of Fabhalta®. NXP200 (HSK42360) Overview, Competitive Landscape and Market Analysis BRAF is a validated therapeutic target in oncology with first generation drugs such as Tafinlar® (dabrafenib, marketed by Novartis) and Braftovi® (encorafenib, marketed by Pfize